TY  - GEN
AU  - Garcia-Sanz, R
AU  - Sureda Gomila, Antoni
AU  - de la Cruz, Fatima
AU  - Canales, M
AU  - Gonzalez, AP
AU  - Pinana, JL
AU  - Rodriguez, A
AU  - Gutierrez, Antonio
AU  - Domingo Domenech, Eva
AU  - Sanchez-Gonzalez, B
AU  - Rodriguez, G
AU  - Lopez, J
AU  - Moreno, M
AU  - Rodriguez-Salazar, MJ
AU  - Jimenez-Cabrera, S
AU  - Caballero, Maria Dolores
AU  - Martinez, C
PY  - 2019
DO  - 10.1093/annonc/mdz009
SN  - 0923-7534
UR  - https://hdl.handle.net/20.500.12105/22781
AB  - Background: In this work, we assessed the efficacy and safety of brentuximab vedotin (BV) plus ESHAP (BRESHAP) as second-line therapy for Relapsed/Refractory Hodgkin lymphoma (RRHL) to improve the results before autologous stem-cell transplantation...
LA  - eng
PB  - Oxford University Press
KW  - Hodgkin lymphoma
KW  - Refractory
KW  - Polychemotherapy
KW  - Brentuximab vedotin
KW  - Transplant
TI  - Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
TY  - research article
ER  -